beta

AGN

Allergan Plc

Agn

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1984 and is headquartered in Dublin, Ireland.

Market Cap: 61.3 Billion

Primary Exchange: New York Stock Exchange

Website: http://www.allergan.com

Shares Outstanding: 328 Million

Float: 328 Million

Dividend: 2.94 (0.02%)

Beta: 0.677360487493601

Sector: Health Technology

Industry: Pharmaceuticals: Generic

Ethical Flags

Animal testing

Longest drawdown: 1628 trading days

From: 2015-07-28 To: 2019-12-11

Lowest Point:

FDA Approves Amgen And Allergan's KANJINTI(TM) (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)

via: PR Newswire at 2019-06-13 15:13:00:000

THOUSAND OAKS, Calif. , June 13, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTI (trastuzumab-anns) for all approved indications of the reference product, Herceptin … read more...

Billionaires Love 50 Stocks And 31 Of Those Pay Dividends

via: SeekingAlpha at 2019-06-13 10:41:44:000

James Brumley says in Kiplinger Investing : "Rich people often get perpetually richer for a reason, so it could be worthwhile to study what billionaires and high-asset hedge funds are plowing their long-term capital into." As any collection of stocks is more clearly understood when subj… read more...

Akero Therapeutics Readies $75 Million IPO

via: SeekingAlpha at 2019-06-13 09:11:26:000

Quick Take Akero Therapeutics ( AKRO ) has filed to raise gross proceeds of $75.0 million from a U.S. IPO, according to an S-1/A registration statement . The firm is developing a treatment for metabolic diseases with high unmet clinical needs, with an initial focus on non-alcoholic steato… read more...

Tracking Wallace Weitz's Weitz Investment Management Portfolio - Q1 2019 Update

via: SeekingAlpha at 2019-06-13 04:50:49:000

This article is part of a series that provides an ongoing analysis of the changes made to Wallace Weitzs 13F portfolio on a quarterly basis. It is based on Weitzs regulatory 13F Form filed on 05/14/2019. Please visit our Tracking Wallace Weitzs Weitz Investment Manag… read more...

Barclays bearish on Teva, sees 14% downside risk in premarket analyst action

via: SeekingAlpha at 2019-06-11 04:46:44:000

Agilent (NYSE: A ) initiated with Overweight rating and $83 (18% upside) price target at Piper Jaffray. More news on: Agilent Technologies, Inc., Danaher Corporation, Teleflex Incorporated, Healthcare stocks news, Stocks on the move, , Read more … read more...

Barclays bearish on Teva, sees 14% downside risk in premarket analyst action

via: SeekingAlpha at 2019-06-11 04:46:44:000

Agilent (NYSE: A ) initiated with Overweight rating and $83 (18% upside) price target at Piper Jaffray. More news on: Agilent Technologies, Inc., Danaher Corporation, Teleflex Incorporated, Healthcare stocks news, Stocks on the move, , Read more … read more...

FDA Ad Com tomorrow on utility of higher-dose opioids

via: SeekingAlpha at 2019-06-10 13:06:51:000

The FDA's Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee will jointly mee t tomorrow and Wednesday, June 11 & 12, to seek public input on the clinical utility and safety concerns associated with higher range opioid an… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
2019-11-12 2019-12-13 2019-11-13 2019-10-25 0.74 Cash
2019-08-12 2019-09-13 2019-08-13 2019-07-19 0.74 No Change QoQ
2019-05-13 2019-06-14 2019-05-14 2019-05-03 0.74 No Change QoQ
2019-02-14 2019-03-15 2019-02-15 2019-01-25 0.74 Increase
2018-11-12 2018-12-14 2018-11-13 2018-10-26 0.72 No Change QoQ
2018-08-16 2018-09-17 2018-08-17 2018-07-30 0.72 No Change QoQ
2018-05-17 2018-06-15 2018-05-18 2018-05-03 0.72 No Change QoQ
2018-02-27 2018-03-28 2018-02-28 2018-02-09 0.72 Increase
2017-11-16 2017-12-15 2017-11-17 2017-10-27 0.7 No Change QoQ
2017-08-16 2017-09-15 2017-08-18 2017-08-02 0.7 No Change QoQ
2017-05-16 2017-06-15 2017-05-18 2017-05-05 0.7 No Change QoQ
2017-02-24 2017-03-28 2017-02-28 2016-11-02 0.7 Initiation
2015-02-05 2015-03-20 2015-02-09 2015-02-04 0.05 No Change QoQ
2014-11-18 2014-12-11 2014-11-20 2014-10-27 0.05 No Change QoQ
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud